Peters, S.
Clézardin, P.
Márquez-Rodas, I.
Niepel, D.
Gedye, C. http://orcid.org/0000-0002-1629-4352
Funding for this research was provided by:
Amgen (Europe) GmbH
Article History
Received: 12 December 2018
Accepted: 18 December 2018
First Online: 17 January 2019
Compliance with ethical standards
:
: SP has received educational grants, provided consultation, attended advisory boards and/or provided lectures for the following organisations: AbbVie, Amgen, AstraZeneca, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Serono, Merck Sharp and Dohme, Merrimack, Novartis, Pfizer, Pharma Mar, Regeneron, Sanofi, Seattle Genetics and Takeda. PC has attended advisory boards and provided lectures for Amgen. IM-R has received grants, travel accommodation, or held an advisory role with Amgen, Bioncotech, Bristol-Myers Squibb, Merck Serono, Merck Sharp and Dohme, Novartis, Pierre Fabre and Roche. DN is an Amgen employee and holds Amgen stock. CG has provided consultation, attended advisory boards, received travel support and/or provided lectures for the following organisations (all fees direct to institution): AbbVie, AstraZeneca, Bristol-Myers Squibb, Ipsen, Merck KGaA, Merck Sharp and Dohme, Pfizer and Sanofi. CG has directed research grant support (all fees direct to institution) from Amgen, Bristol-Myers Squibb and Merck Sharp and Dohme. CG is a consultant for Novotech CRO Pty and is the coordinating principal investigator of the ANZUP-sponsored KEYPAD study.
: The manuscript does not report clinical or patient data acquired by any of the authors.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: The manuscript does not report clinical or patient data acquired by any of the authors.